Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Single-dose, Open-label Study to Investigate the Pharmacokinetics and Safety of PKN605 in Participants With Moderate and Severe Renal Impairment Compared to Matched Control Healthy Participants With Normal Renal Function

NCT07797322 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT07797322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07797322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Single-dose, Open-label Study to Investigate the Pharmacokinetics and Safety of PKN605 in Participants With Moderate and Severe Renal Impairment Compared to Matched Control Healthy Participants With Normal Renal Function
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
February 18, 2027
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

participants with moderate and severe renal impairment and healthy participants